Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. $1177.HK
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS12
PHASE 3 / 2-35
RECRUITING6
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO20%
Delay Index: of 5 active trials registered more than a year ago, 1 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. on the live radar map → 📅 $1177.HK readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection NCT06854445 |
P2 | Recruiting | Diffuse Large Cell B-lymphoma | 55 | 2025-10 |
| TQH2722 injection NCT07398859 |
P2 | Recruiting | Seasonal Allergic Rhinitis | 300 | 2026-11 |
| TQC2731 injection NCT06707883 |
P2 | Active, not recruiting | Chronic Obstructive Pulmonary Disease | 258 | 2026-12 |
| TQC2731 injection NCT07107256 |
P3 | Active, not recruiting | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 246 | 2027-03 |
| Kylo 0603 Capsule 8mg NCT07878091 |
P2 | Not yet recruiting | Metabolic Dysfunction-Associated Steatoic Liver Disease | 120 | 2027-08-15 |
| TQB2922 injection (subcutaneous administration) NCT07844187 |
P1/2 | Not yet recruiting | Colorectal Neoplasms | 64 | 2027-08-31 |
| TQC2731 injection NCT06829784 |
P3 | Recruiting | Asthma | 660 | 2027-12 (+6 mo) |
| TQB2868 Injection NCT07165951 |
P3 | Recruiting | Metastatic Pancreatic Ductal Adenocarcinoma | 566 | 2028-05 |
| TQB2825 Injection NCT07187960 |
P3 | Not yet recruiting | Follicular Lymphoma | 228 | 2028-10 |
| LM-302 Injection NCT07385703 |
P3 | Recruiting | Adenocarcinoma | 752 | 2028-10 |
| TQB2922 Subcutaneous Injection NCT07601204 |
P1/2 | Not yet recruiting | Recurrent/Metastatic Head and Neck Cancer | 128 | 2029-02 |
| TQB2934 injection NCT07266116 |
P1/2 | Recruiting | Systemic Light Chain Amyloidosis | 70 | 2029-02 |